Perrigo just rose 23.1% in a single session, which indicates sentiment shifted far faster than the underlying story changed. The stock entered this report trading on a low trailing price-to-sales ratio of 0.4x, far below the broader pharmaceuticals group, and investors finally treated that discount as more than background noise.

The main focus is profit tone, not revenue. After a string of heavy losses, Perrigo posted Q2 basic earnings per share of US$0.64, and net income from continuing operations returned to positive territory for the quarter, even as trailing 12-month results still show a large loss. Today’s move reflects the market placing more weight on this quarter’s profitability than on the loss recorded over the last year.

Is Perrigo a genuine deep value opportunity after this 23.1% spike, or is the low 0.4x P/S multiple just masking unresolved issues in the trailing loss profile? Compare the current share price against our detailed valuation analysis for Perrigo

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$1,022.8 million vs. US$1,056.3 million (modest year on year decline)
• Net Income from Continuing Operations (Q2 2026 vs. Q2 2025): US$88.6 million vs. a loss of US$0.5 million (returned to profit from a small loss)
• Basic EPS (Earnings per Share) (Q2 2026 vs. Q2 2025): US$0.64 vs. a loss of US$0.00 (moved from roughly breakeven to positive earnings per share)
• Core Adjusted Operating Margin (Q2 2026 vs. Q2 2025): 13.0% vs. roughly 14.6% (core margin compressed by about 160 basis points)

Prefer clear charts over dense earnings tables and footnotes? View Perrigo’s full financial picture and see a visual representation of its recent profitability trend in the company report for Perrigo.

Perrigo Bull Story Meets Hard Profit Milestones

Bulls argue Perrigo can turn portfolio simplification and tighter cost control into higher margins and stronger cash generation. Q2 did mark some concrete progress on that script. Net income from continuing operations moved into profit at US$88.6 million and basic EPS reached US$0.64, which shows the business can generate earnings even while core organic sales declined 3.5% and core margins compressed.

The narrative also leans on better execution with major retailers. Service levels near 91% in the U.S. and 95% internationally, together with modest share gains in weak categories, support the idea that Perrigo is becoming a more reliable store brand supplier. On portfolio actions, roughly US$600 million of divestiture proceeds since 2024 and the Dermacosmetics sale used mainly for debt reduction align with the promise of simplification and deleveraging, even though full margin recovery is not yet evident in the quarterly figures.

Compare Perrigo’s internal progress on margins and earnings with what institutions are actually pricing in. See the consensus price target analysis for Perrigo to check whether Wall Street’s targets line up with this turnaround story.

Perrigo Bears Still See Margin And Leadership Gaps

The core bearish worry is that Perrigo is a value trap, with restructuring and debt reduction failing to fix weak growth, pressured margins and leadership risk. This quarter gives bears fresh talking points. Core organic sales fell 3.5% and core net sales declined 3.1%. That aligns with concerns about soft OTC categories and retailer destocking. Core adjusted gross margin compressed by about 250 bps and core adjusted operating margin fell to 13.0%, so Project Energize and Supply Chain Reinvention are not yet offsetting category and cost pressure. Core adjusted EPS of US$0.46 also slipped year on year and relied on about US$16 million of one time benefits, which supports the view that earnings quality is still mixed.

Leadership risk also remains a live issue, with an interim CEO in place and executive severance protections reinstated. That fits the bearish focus on execution uncertainty.

With Perrigo still working through leadership uncertainty, weaker core margins and a stretched dividend payout, it is worth asking whether these are isolated issues or hints of something deeper.

Stay Ahead With Perrigo And Simply Wall St

If Perrigo’s sharp 23.1% move and low 0.4x P/S ratio have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis evolves from here. When you decide to take a position, keep on top of what matters using the Portfolio Command Center that cuts through noise and surfaces only the most important updates on your holdings. For a wider lens on Perrigo and comparable stocks, use the Community to see how other investors are interpreting the same numbers and risks. By spotting potential catalysts and pressure points early, you give yourself more opportunity to react quickly and stay in front of the market.

Curious About Alternatives Worth Exploring

Fresh opportunities do not wait. Some stocks are building quiet breakout momentum, others are dropping into attractive ranges. Scan these ideas before the crowd catches on and act now.

• Spot resilient companies with room to run and check the 79 resilient stocks with low risk scores while it still focuses on stocks that remain under the radar for now.
• Chase compounding income potential by scanning the 8 dividend fortresses before yields get compressed and the strongest payers are priced for perfection.
• Track real businesses behind the AI buzz and review the 67 profitable AI stocks that aren't just burning cash while the most balanced opportunities are still flying below broad market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.